A Nephrology Associates, PC Initiative
Southeastern Clinical Research Institute.
Advancing the next generation of kidney care for the Central Savannah River Area, where rigorous, ethically governed nephrology trials give our patients first access to tomorrow's therapies.
The standard of care started as someone's trial.
Southeastern Clinical Research Institute is the dedicated trials arm of Nephrology Associates, PC, conducting clinical research for more than 25 years. We exist to bring rigorously studied, next-generation kidney therapies to the people of the CSRA, years before they reach general practice, without ever compromising the safety, dignity, or consent of the patients who make that progress possible.
Every study is governed by an independent Institutional Review Board, run by a Good Clinical Practice trained team, and overseen by the same board-certified nephrologists who care for our patients every day. Research here is not separate from care. It is an extension of it.
Matthew Diamond, DO · Director, Southeastern Clinical Research Institute
Where our research is focused.
Our investigators concentrate on the conditions that drive the greatest burden of kidney disease across the Southeast.
Chronic Kidney Disease
Cardiovascular Disease
Anemia
Diabetes Mellitus
Dialysis Access
Hyperparathyroidism
Hyperphosphatemia
Hypertension
Iron Deficiency
Glomerulonephritis
Proteinuria
Hyperlipidemia
Kidney Disease
Immunology
Polycystic Kidney Disease
Lupus Nephritis
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Care that looks forward.
Joining a study is a personal decision, and an entirely voluntary one. For many of our patients, it means closer monitoring, more time with the care team, and a chance to help the next person with kidney disease.
Carefully selected investigational therapies, years before they reach general use.
Additional labs, visits, and study-team attention throughout your participation.
Study-related visits, tests, and the investigational therapy are provided at no cost.
Participation is voluntary, fully consented, and you may withdraw at any time.
Current studies, at a glance.
A snapshot of representative trials. Specific eligibility is confirmed by our study team. Listings update as protocols open and close.
CKD Progression
A randomized study of a disease-modifying agent in adults with stage 3–4 chronic kidney disease and proteinuria.
Diabetic Kidney Disease
Evaluating a next-generation therapy to slow decline of kidney function in type 2 diabetes.
IgA Nephropathy
An investigational immunomodulator for biopsy-confirmed IgA nephropathy with persistent proteinuria.
Refer a patient, keep the loop closed.
Refer a patient for a research evaluation and you stay informed at every step. We confirm eligibility, manage all study-related care, and report back to you directly, while your patient remains yours.
- OversightIRB-approved protocols, GCP-trained team
- DirectorMatthew Diamond, DO · Principal Investigator
- CommunicationDirect physician-to-physician reporting
- ContinuityYour patient stays under your care